Illumina (MEX:ILMN) Intrinsic Value: Projected FCF: MXN816.24 (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ILMN Illumina Inc MEX:ILMN
54 GF Score
Price MXN3,637.34
GF Value MXN2,211.71
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Illumina Intrinsic Value: Projected FCF?

Illumina MEX:ILMN 54 Intrinsic Value: Projected FCF is MXN816.24 as of Sep. 05, 2026. GuruFocus rates MEX:ILMN with a GF Score™ of 54/100 and a GF Value™ of MXN2,211.71 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 106 Medical Diagnostics & Research companies, Illumina ranks worse than 85.85% on this metric.

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2026-09-05), Illumina's Intrinsic Value: Projected FCF is MXN816.24. The stock price of Illumina is MXN3637.34. Therefore, Illumina's Price-to-Intrinsic-Value-Projected-FCF of today is 4.5.

The historical rank and industry rank for Illumina's Intrinsic Value: Projected FCF or its related term are showing as below:

MEX:ILMN' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.76   Med: 3.25   Max: 5.48
Current: 4.46

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Illumina was 5.48. The lowest was 1.76. And the median was 3.25.

MEX:ILMN's Price-to-Projected-FCF is ranked worse than
85.85% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.465 vs MEX:ILMN: 4.46

Illumina  (MEX:ILMN) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Illumina's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3637.34/919.47266439842
=3.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Illumina Intrinsic Value: Projected FCF Related Terms


Illumina Intrinsic Value: Projected FCF Historical Data

* Premium members only.

The historical data trend for Illumina's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina Intrinsic Value: Projected FCF Chart

Illumina Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,330.53 1,387.14 1,098.76 928.37 920.39

Illumina Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 808.60 908.43 920.39 872.17 779.82

MEX:ILMN vs MTD, LH, DGX: Intrinsic Value: Projected FCF Comparison

For the Diagnostics & Research subindustry, Illumina's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina Price-to-Projected-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Illumina's Price-to-Projected-FCF falls into.


MEX:ILMN
54GF Score
Illumina Inc MEX:ILMN
Intrinsic Value: Projected FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Illumina Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Illumina's Free Cash Flow(6 year avg) = MXN10,615.48.

Illumina's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jun26)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*10615.48064+49520.262*0.8)/153.000
=919.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Intrinsic Value: Projected FCF of MXN816.24 mean?
Illumina (MEX:ILMN) has a Intrinsic Value: Projected FCF of MXN816.24 as of Sep. 05, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Illumina and its competitors. According to the industry distribution chart, Illumina ranks #91 out of 106 companies in the Medical Diagnostics & Research industry, placing it in the top 85.8%.
Is Illumina's Intrinsic Value: Projected FCF too high?
Illumina's current Intrinsic Value: Projected FCF is MXN816.24. Based on the distribution chart, Illumina ranks #91 out of 106 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Illumina has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's Intrinsic Value: Projected FCF compare to MTD and LH?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #91 out of 106 companies for Intrinsic Value: Projected FCF. This places Illumina in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Diagnostics & Research company?
The median Intrinsic Value: Projected FCF among Medical Diagnostics & Research companies is 1.47, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median Intrinsic Value: Projected FCF is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current Intrinsic Value: Projected FCF is MXN816.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (MEX:ILMN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,211.71, compared to a current price of MXN3,637.34 — trading 64.5% above its estimated fair value. The current Intrinsic Value: Projected FCF is MXN816.24. Illumina's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Illumina (MEX:ILMN), the current Intrinsic Value: Projected FCF is MXN816.24 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Illumina (MEX:ILMN) Overvalued in 2026?

Based on GuruFocus' analysis, Illumina stock appears to be overvalued. The current stock price of MXN3,637.34 is trading 64.5% above its estimated GF Value™ of MXN2,211.71. GuruFocus considers Illumina to be Significantly Overvalued.

Key valuation signals for MEX:ILMN:

  • Intrinsic Value: Projected FCF: MXN816.24
  • GF Value™: MXN2,211.71 vs. price of MXN3,637.34 (64.5% above fair value)
  • GF Score™: 54/100 with 7 warning signs

No single metric tells the full story. See the MEX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Illumina Business Description

Address 5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
54GF Score

Get the complete analysis for MEX:ILMN

Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,637.34
Price
MXN2,211.71
GF Value